CN1788753A - 一种丹皮总苷提取物及其制备方法和用途 - Google Patents
一种丹皮总苷提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN1788753A CN1788753A CN 200410075494 CN200410075494A CN1788753A CN 1788753 A CN1788753 A CN 1788753A CN 200410075494 CN200410075494 CN 200410075494 CN 200410075494 A CN200410075494 A CN 200410075494A CN 1788753 A CN1788753 A CN 1788753A
- Authority
- CN
- China
- Prior art keywords
- root bark
- tree peony
- peony root
- cortex moutan
- glycoside extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 150000002338 glycosides Chemical class 0.000 title claims description 118
- 229930182470 glycoside Natural products 0.000 title claims description 111
- 240000005001 Paeonia suffruticosa Species 0.000 title claims description 32
- 235000003889 Paeonia suffruticosa Nutrition 0.000 title claims description 32
- 239000003814 drug Substances 0.000 claims abstract description 28
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 7
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 45
- 238000002347 injection Methods 0.000 claims description 33
- 239000007924 injection Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 235000019441 ethanol Nutrition 0.000 claims description 16
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 208000028867 ischemia Diseases 0.000 claims description 9
- 210000000115 thoracic cavity Anatomy 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims description 5
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 claims description 3
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 claims description 3
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229930182487 phenolic glycoside Natural products 0.000 claims description 3
- 150000007950 phenolic glycosides Chemical class 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 pulverize Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 4
- AVIUTYMRHHBXPB-UXXRCYHCSA-N Paeonoside Natural products COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 AVIUTYMRHHBXPB-UXXRCYHCSA-N 0.000 abstract 3
- AVIUTYMRHHBXPB-UHFFFAOYSA-N glucopaeonol Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(CO)O2)O)=C1 AVIUTYMRHHBXPB-UHFFFAOYSA-N 0.000 abstract 3
- XFFQVRFGLSBFON-DEFKTLOSSA-N kaempferol 3,7-di-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-DEFKTLOSSA-N 0.000 abstract 3
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 30
- 210000003462 vein Anatomy 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000004351 coronary vessel Anatomy 0.000 description 10
- 241000628997 Flos Species 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 238000012109 statistical procedure Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 206010057362 Underdose Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 3
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 230000003601 intercostal effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000000779 thoracic wall Anatomy 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- ZGZLYKUHYXFIIO-UHFFFAOYSA-N 5-nitro-2h-tetrazole Chemical compound [O-][N+](=O)C=1N=NNN=1 ZGZLYKUHYXFIIO-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 行为障碍 | 缺血面积(%) | |
假手术组模型对照组Nim组丹皮总苷组 | 3mg/kg9mg/kg27mg/kg | 011.21±1.476.54±2.71**8.02±1.44*7.10±3.03*6.14±1.28** | 024.21±4.3113.17±7.17**19.11±3.73*17.51±2.84*12.18±3.54** |
810mg/kg | 4.23±1.13*** | 10.87±3.01*** | |
芍药苷 | 3mg/kg | 8.25±1.57* | 20.01±2.75* |
9mg/kg | 7.49±2.01* | 18.49±3.13* | |
27mg/kg | 6.99±2.25** | 13.91±3.18** |
组别 | 剂量mg/kg | J点抬高数值(mv) | |||||
5min | 30min | 60min | 90min | 180min | 240min | ||
模型组 | - | 0.27±0.10 | 0.26±0.04 | 0.26±0.04 | 0.25±0.05 | 0.25±0.04 | 0.25±0.05 |
丹皮总苷 | 3927810 | 0.25±0.070.24±0.060.22±0.04*0.20±0.04* | 0.25±0.040.22±0.04*0.21±0.05*0.19±0.07* | 0.23±0.04*0.22±0.05*0.20±0.06**0.18±0.04** | 0.23±0.090.23±0.090.20±0.07*0.19±0.05** | 0.24±0.080.22±0.100.21±0.06*0.20±0.07* | 0.23±0.070.21±0.090.21±0.080.20±0.06 |
红花注射液 | 150 | 0.23±0.05 | 0.22±0.05* | 0.21±0.07* | 0.21±0.07* | 0.21±0.08 | 0.21±0.09 |
芍药苷 | 3927 | 0.26±0.050.25±0.040.23±0.05* | 0.25±0.070.24±0.03*0.22±0.04* | 0.24±0.02*0.24±0.02*0.21±0.03** | 0.25±0.040.23±0.080.22±0.04* | 0.24±0.070.23±0.100.23±0.06 | 0.24±0.060.24±0.050.23±0.08 |
组别 | 剂量mg/kg | CK酶活U/L | AST酶活U/L | LDH酶活U/L |
假手术组模型组丹皮总苷 | --3927810 | 881.27±133.641231.78±79.31###1219.71±147.311109.37±121.35*1002.73±192.81*971.47±159.2* | 80.14±22.00157.62±27.6###120.69±24.39*113.63±34.10*103.45±31.6**99.31±41.49** | 186.45±43.46470.94±25.04###374.16±67.63*348.35±62.73*312.19±59.81***297.37±73.58*** |
红花注射液 | 150 | 1104.41±93.91* | 115.58±29.34* | 363.71±53.51* |
芍药苷 | 3927 | 1314.21±122.751089.13±117.31*998.34±201.81* | 121.51±36.12*117.37±30.31*107.75±32.17** | 383.16±66.11*331.21±49.71*309.37±83.35** |
组别 | 剂量(mg/kg) | 心肌梗死重量百分率(%) |
模型组丹皮总苷 | -3927810 | 26.12±1.7123.54±3.71*22.87±3.25*21.59±2.57**20.17±3.07** |
红花注射液 | 150 | 22.49±4.20* |
芍药苷 | 3937 | 24.37±2.0123.12±3.01*21.47±2.62** |
组别 | 剂量(mg/kg) | 凝血时间(s) |
正常组丹皮总苷 | -61854 | 103±20.02154±26.89**152.5±31.9**199.6±33.40*** |
芍药苷 | 61854 | 160.10±37.74**170.11±37.15**180.57±32.65*** |
组别 | 剂量(mg/kg) | 存活时间(min) |
正常组丹皮总苷 | -61854 | 24.75±1.5227.26±2.01*32.15±2.92**40.17±3.14*** |
芍药苷 | 61854 | 26.72±2.73*28.13±2.23**30.57±3.39** |
组别 | 剂量(mg/kg) | 喘气时间(s) |
正常组丹皮总苷 | -61854 | 20.19±1.4122.37±1.13*24.27±1.97**25.36±2.71** |
芍药苷 | 61854 | 22.12±1.11*23.47±2.06*24.24±1.74** |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410075494 CN1788753B (zh) | 2004-12-16 | 2004-12-16 | 一种丹皮总苷提取物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410075494 CN1788753B (zh) | 2004-12-16 | 2004-12-16 | 一种丹皮总苷提取物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1788753A true CN1788753A (zh) | 2006-06-21 |
CN1788753B CN1788753B (zh) | 2010-12-08 |
Family
ID=36786997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410075494 Expired - Fee Related CN1788753B (zh) | 2004-12-16 | 2004-12-16 | 一种丹皮总苷提取物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1788753B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181373B (zh) * | 2007-12-07 | 2010-12-22 | 戴敏 | 丹皮有效部位药物组合物、其制备方法及应用 |
CN102416047A (zh) * | 2011-11-17 | 2012-04-18 | 上海中医药大学 | 牡丹皮提取物及丹皮酚的医药用途 |
CN103180334A (zh) * | 2010-11-10 | 2013-06-26 | 张作光 | 制备芍药内酯苷和芍药苷的方法 |
CN103327992A (zh) * | 2010-12-03 | 2013-09-25 | 信一制药株式会社 | 用于预防或治疗炎性疾病的包含络石藤提取物和牡丹皮提取物的药物组合物以及制备该药物组合物的方法 |
-
2004
- 2004-12-16 CN CN 200410075494 patent/CN1788753B/zh not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181373B (zh) * | 2007-12-07 | 2010-12-22 | 戴敏 | 丹皮有效部位药物组合物、其制备方法及应用 |
CN103180334A (zh) * | 2010-11-10 | 2013-06-26 | 张作光 | 制备芍药内酯苷和芍药苷的方法 |
EP2650301A1 (en) * | 2010-11-10 | 2013-10-16 | Zuoguang Zhang | Method for preparing albiflorin and paeoniflorin |
EP2650301A4 (en) * | 2010-11-10 | 2014-04-23 | Zuoguang Zhang | PROCESS FOR THE PREPARATION OF ALBIFLORIN AND PAEONIFLORIN |
US9453041B2 (en) | 2010-11-10 | 2016-09-27 | Zuoguang Zhang | Method for preparing albiflorin and paeoniflorin |
CN103327992A (zh) * | 2010-12-03 | 2013-09-25 | 信一制药株式会社 | 用于预防或治疗炎性疾病的包含络石藤提取物和牡丹皮提取物的药物组合物以及制备该药物组合物的方法 |
CN103327992B (zh) * | 2010-12-03 | 2016-10-12 | 信一制药株式会社 | 用于预防或治疗炎性疾病的包含络石藤提取物和牡丹皮提取物的药物组合物以及制备该药物组合物的方法 |
US9694045B2 (en) | 2010-12-03 | 2017-07-04 | Sinil Pharmaceutical Co., Ltd. | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same |
CN102416047A (zh) * | 2011-11-17 | 2012-04-18 | 上海中医药大学 | 牡丹皮提取物及丹皮酚的医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1788753B (zh) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104491350A (zh) | 一种调节心脑血管健康和减少心脑血管疾病风险的保健品 | |
CN104224885A (zh) | 一种缓解体力疲劳的中药组合物 | |
CN1814170A (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
CN1788753A (zh) | 一种丹皮总苷提取物及其制备方法和用途 | |
CN102731597A (zh) | 黄蜀葵花提取物及其化学成分的新用途 | |
CN1803182A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN1919239A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN1883498A (zh) | 用于治疗心脑血管疾病的药物——复方葛根素 | |
CN101028437A (zh) | 一种防治心脑血管疾病的中药有效部位组合物及制备方法 | |
CN1895540A (zh) | 一种治疗心血管疾病的药物组合物及其制备方法和用途 | |
CN1823875A (zh) | 一种瓜蒌皮的药物组合物及其制备方法 | |
CN1853688A (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN106138217B9 (zh) | 桑椹颗粒在制备防治糖尿病及其并发症药物中的应用 | |
CN101744806A (zh) | 松属素外消旋体在制备治疗脑卒中药物中的用途 | |
CN1765357A (zh) | 红花黄色素b在制备治疗心脑血管疾病的药物中的应用 | |
CN101032534A (zh) | 救必应总皂苷的制备方法及应用 | |
CN1291727C (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN1582946A (zh) | 积雪草酸衍生物在制备防治心、脑血管疾病的药物中的用途 | |
CN101361841A (zh) | 一种中药组合物在制备治疗糖尿病性心肌病的药物中的应用 | |
CN1279919C (zh) | 一种含人参总皂苷、红花黄色素的药物组合物及其制备和应用 | |
CN108126116A (zh) | 一种全天麻片的制备工艺 | |
CN107820427A (zh) | 草质素或其组合物在制备防治心脑血管疾病药物中的应用 | |
CN1181840C (zh) | 广东海风藤及其提取物在制备治疗阿尔茨海默病或脑缺血脑部疾病的药物中的应用 | |
CN1305493C (zh) | 一种治疗脑中风的中药有效部位及其分离制备方法 | |
CN1919242A (zh) | 治疗心脑血管疾病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Gao Yubai Inventor after: Sun Lifang Inventor after: Wang Chaoyun Inventor after: Zhang Taiping Inventor after: Meng Ying Inventor after: Sun Fang Inventor before: Gao Yubai Inventor before: Wang Chaoyun Inventor before: Zhang Taiping Inventor before: Sun Fang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GAO YUBAI WANG CHAOYUN ZHANG TAIPING SUN FANG TO: GAO YUBAI SUN LIFANG WANG CHAOYUN ZHANG TAIPING MENG YING SUN FANG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170608 Address after: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101208 Termination date: 20181216 |